CIBC Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $730K | Buy |
5,544
+1,121
| +25% | +$149K | ﹤0.01% | 738 |
|
|
2025
Q4 | $627K | Buy |
4,423
+1,290
| +41% | +$187K | ﹤0.01% | 758 |
|
|
2025
Q3 | $440K | Hold |
3,133
| – | – | ﹤0.01% | 805 |
|
|
2025
Q2 | $394K | Sell |
3,133
-1,155
| -27% | -$132K | ﹤0.01% | 804 |
|
|
2025
Q1 | $474K | Buy |
4,288
+210
| +5% | +$26.6K | ﹤0.01% | 761 |
|
|
2024
Q4 | $557K | Buy |
4,078
+487
| +14% | +$60.2K | ﹤0.01% | 735 |
|
|
2024
Q3 | $414K | Buy |
3,591
+191
| +6% | +$26.2K | ﹤0.01% | 784 |
|
|
2024
Q2 | $468K | Buy |
3,400
+153
| +5% | +$21K | ﹤0.01% | 750 |
|
|
2024
Q1 | $448K | Buy |
3,247
+7
| +0.2% | +$956 | ﹤0.01% | 749 |
|
|
2023
Q4 | $427K | Sell |
3,240
-229
| -7% | -$26.4K | ﹤0.01% | 745 |
|
|
2023
Q3 | $390K | Buy |
3,469
+48
| +1% | +$5.05K | ﹤0.01% | 747 |
|
|
2023
Q2 | $323K | Buy |
3,421
+3
| +0.1% | +$293 | ﹤0.01% | 798 |
|
|
2023
Q1 | $346K | Buy |
3,418
+325
| +11% | +$33.8K | ﹤0.01% | 770 |
|
|
2022
Q4 | $369K | Sell |
3,093
-1,163
| -27% | -$136K | ﹤0.01% | 763 |
|
|
2022
Q3 | $452K | Buy |
4,256
+12
| +0.3% | +$1.22K | ﹤0.01% | 787 |
|
|
2022
Q2 | $414K | Sell |
4,244
-59
| -1% | -$5.45K | ﹤0.01% | 784 |
|
|
2022
Q1 | $403K | Buy |
4,303
+24
| +0.6% | +$2.03K | ﹤0.01% | 903 |
|
|
2021
Q4 | $364K | Buy |
4,279
+423
| +11% | +$38.9K | ﹤0.01% | 961 |
|
|
2021
Q3 | $370K | Buy |
3,856
+338
| +10% | +$31.9K | ﹤0.01% | 920 |
|
|
2021
Q2 | $342K | Buy |
3,518
+6
| +0.2% | +$575 | ﹤0.01% | 933 |
|
|
2021
Q1 | $342K | Sell |
3,512
-10,734
| -75% | -$1.13M | ﹤0.01% | 908 |
|
|
2020
Q4 | $1.36M | Buy |
14,246
+818
| +6% | +$79K | 0.01% | 567 |
|
|
2020
Q3 | $1.29M | Buy |
13,428
+10,053
| +298% | +$1.16M | 0.01% | 531 |
|
|
2020
Q2 | $412K | Hold |
3,375
| – | – | ﹤0.01% | 722 |
|
|
2020
Q1 | $292K | Hold |
3,375
| – | – | ﹤0.01% | 741 |
|
|
2019
Q4 | $363K | Buy |
3,375
+194
| +6% | +$20.3K | ﹤0.01% | 808 |
|
|
2019
Q3 | $287K | Hold |
3,181
| – | – | ﹤0.01% | 860 |
|
|
2019
Q2 | $269K | Hold |
3,181
| – | – | ﹤0.01% | 901 |
|
|
2019
Q1 | $280K | Hold |
3,181
| – | – | ﹤0.01% | 866 |
|
|
2018
Q4 | $227K | Hold |
3,181
| – | – | ﹤0.01% | 885 |
|
|
2018
Q3 | $391K | Hold |
3,181
| – | – | ﹤0.01% | 773 |
|
|
2018
Q2 | $313K | Buy |
3,181
+215
| +7% | +$19.2K | ﹤0.01% | 816 |
|
|
2018
Q1 | $246K | Hold |
2,966
| – | – | ﹤0.01% | 882 |
|
|
2017
Q4 | $230K | Buy |
+2,966
| New | +$202K | ﹤0.01% | 942 |
|
Other funds holding NBIX
VPM
VCM
CIBC Asset Management's NBIX Position: Q1 2026 in Review
CIBC Asset Management increased its Neurocrine Biosciences (NBIX) stake by 25% in Q1 2026, buying an estimated $149K and bringing the position to 5,544 shares worth $730K. The position accounts for ﹤0.01% of the portfolio, ranked #738.
CIBC Asset Management first reported a position in NBIX in Q4 2017 and has held it in 34 quarters since. The position peaked at $1.36M in Q4 2020. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- CIBC Asset Management held 5,544 shares of Neurocrine Biosciences worth $730K as of Q1 2026.
- CIBC Asset Management bought 1,121 Neurocrine Biosciences shares in Q1 2026, an estimated $149K.
- Neurocrine Biosciences made up ﹤0.01% of CIBC Asset Management's portfolio in Q1 2026, its #738 holding.
- CIBC Asset Management first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 34 quarters since.
- CIBC Asset Management's Neurocrine Biosciences position peaked at $1.36M in Q4 2020.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on CIBC Asset Management's 13F filing for Q1 2026, filed 12 May 2026.